Hybrid Pharma, LLC, Deerfield Beach, CA

Is Hybrid Pharma, LLC registered with the FDA as a 503B outsourcing facility?

Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Hybrid Pharma, LLC in Deerfield Beach, CA, first registered Jan 14, 2015 and most recently registered Dec 16, 2025.

Does Hybrid Pharma, LLC hold a California pharmacy license?

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones.

Has Hybrid Pharma, LLC had a state board action or FDA letter?

FDA letters: no matching record found. No entry for Hybrid Pharma, LLC was matched by name and location on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026. The page does list Hybrid Pharma LLC in Deerfield Beach, FL, a close but not exact match shown below. State board actions: no California State Board of Pharmacy action under this exact name and city was found in the board’s posted disciplinary decisions on facility licenses (actions dated Jan 5, 2005 to Oct 28, 2026) on Nov 6, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Hybrid Pharma, LLC
Location
Deerfield Beach, CA
Type as FDA labels it
503B
FDA 503B list
Listed as Hybrid Pharma, LLC
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
None listed
FDA Data Dashboard inspections
No matching site found
State board records
No exact match

FDA inspections and letters

No entry for this name and location was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). That page covers actions from 2019 on; FDA keeps earlier ones in its archive.

FDA inspection classifications and published Form 483s

No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.

State board of pharmacy records

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.

What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.

FDA’s 503B list

Close but not exact matches

These FDA records share a name or a former name with this pharmacy but did not meet this index’s matching rule (the same legal name with the same legal ending, in the same city and state), so they are kept on their own pages. Check them against the pharmacy you are looking for.

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 4 products naming semaglutide and tirzepatide under the labeler name “Hybrid Pharma”, matched to this pharmacy page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (4). The compounded product reports cover FDA reporting periods 2024-2 to 2026-1.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
26436-5608SEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1, 2026-1Compounded drugs
26436-5635SEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1, 2026-1Compounded drugs
26436-5622TIRZEPATIDE 10MG/MLTIRZEPATIDE 10MG/MLINJECTION, SOLUTIONSUBCUTANEOUS10 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1, 2025-2, 2026-1Compounded drugs
26436-5636TIRZEPATIDE 20MG/MLTIRZEPATIDE 20MG/MLINJECTION, SOLUTIONSUBCUTANEOUS20 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1, 2025-2, 2026-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.